Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kowey

Showing results (291-300 of 451) with videos related to

Pageof 46
Sort By:
JACC. Clinical Electrophysiology|May 16, 2018
Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional MeasuresMarwan Badri, Aashay Patel, Chinmay Patel, et al.
Journal of Atrial Fibrillation|December 19, 2017
Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF StudySergio Conti, James A Reiffel, Bernard J Gersh, et al.
Journal of the American College of Cardiology|August 1, 1996
Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold InvestigatorsS K Stevens, C I Haffajee, G V Naccarelli, et al.
American Heart Journal|March 31, 2015
Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research ConsortiumPhilip T Sager, Jonathan Seltzer, J Rick Turner, et al.
Clinical Cardiology|December 4, 2014
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agentsFederico Guerra, Stefan H Hohnloser, Peter R Kowey, et al.
Circulation. Arrhythmia and Electrophysiology|December 2, 2009
Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trialPeter R Kowey, Paul Dorian, L Brent Mitchell, et al.
Journal of Clinical Pharmacology|April 20, 2018
Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and PharmacyJ Rick Turner, Ignacio Rodriguez, Emily Mantovani, et al.
American Heart Journal|July 29, 2008
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudySripal Bangalore, Franz H Messerli, Jerome D Cohen, et al.
Circulation|February 13, 2003
Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?Victor A Medina-Ravell, Ramarao S Lankipalli, Gan-Xin Yan, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 28, 2018
A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillationA John Camm, Paul Dorian, Stefan H Hohnloser, et al.
Pageof 46

Showing results (291-300 of 451) with videos related to

Sort By:
Pageof 46
JACC. Clinical Electrophysiology|May 16, 2018
Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional MeasuresMarwan Badri, Aashay Patel, Chinmay Patel, et al.
Journal of Atrial Fibrillation|December 19, 2017
Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF StudySergio Conti, James A Reiffel, Bernard J Gersh, et al.
Journal of the American College of Cardiology|August 1, 1996
Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold InvestigatorsS K Stevens, C I Haffajee, G V Naccarelli, et al.
American Heart Journal|March 31, 2015
Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research ConsortiumPhilip T Sager, Jonathan Seltzer, J Rick Turner, et al.
Clinical Cardiology|December 4, 2014
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agentsFederico Guerra, Stefan H Hohnloser, Peter R Kowey, et al.
Circulation. Arrhythmia and Electrophysiology|December 2, 2009
Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trialPeter R Kowey, Paul Dorian, L Brent Mitchell, et al.
Journal of Clinical Pharmacology|April 20, 2018
Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and PharmacyJ Rick Turner, Ignacio Rodriguez, Emily Mantovani, et al.
American Heart Journal|July 29, 2008
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudySripal Bangalore, Franz H Messerli, Jerome D Cohen, et al.
Circulation|February 13, 2003
Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?Victor A Medina-Ravell, Ramarao S Lankipalli, Gan-Xin Yan, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 28, 2018
A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillationA John Camm, Paul Dorian, Stefan H Hohnloser, et al.
Pageof 46